
Brian Callahan wanted to be the next Bob Dylan. Instead, he became a big-time bartender.
There are two of us, Zimu Chen and me. I'll be the owner and also in service on the floor, starting out in a beverage director-ish kind of role.
Darling is a cocktail bar, a small plates restaurant. It was inspired by the phrase 'kill your darlings,' which I interpret as a creative approach to operating without attachment, having the ability to not put boundaries on the cocktail menu and change it at whim.
Advertisement
I really just wanted to do something that utilized a lot of really interesting seasonal ingredients and didn't want to have a ton of rules around it.
People knew the space as
for so long. How did you come to find this space and settle on this location?
I came across the space through [real estate advisory firm] Graffito. We'd been trying to find a space for about a year-and-a-half to two years.
Advertisement
We knew MIT was the owner. When we first inquired about it, we thought it was out of our league. You know, it's MIT; they probably want somebody with a lot more concepts and a lot more experience.
But we also felt like our concept really fit well in the space and in Central Square. We got the opportunity to go speak with MIT and explain our concept and who we are. We put together a whole presentation and everything, and they ended up picking us. We were obviously over the moon — and a little bit surprised.
When you say that MIT owns it, who did you have to pitch your concept to? I picture a bunch of scientists and professors.
They have a whole real estate investment team, but they were incredibly down to earth. We went up to their offices, and it kind of felt like you were on 'Shark Tank,' just pitching your idea. I had a PowerPoint and everything, and it was intimidating. These people are incredibly smart and successful. I'm just a bartender — not just a bartender, but I wasn't a businessman like that. That was the intimidating part of it.
We really learned all this stuff on the fly. We had to learn how to write a business plan, a pitch deck, and everything. We had to learn how to read legal documents and negotiate a lease. Hopefully, if there is a next time, it'll be much easier.
What was your elevator pitch?
We came extremely prepared. We made it clear that we really wanted it. And we explained that Mary Chung was a neighborhood restaurant. It was a family-owned restaurant: The community, the people who came there, knew the people who owned it. They knew their faces. They saw them there every day. And that was what we were. We're not a family restaurant, but we're going to be here every day. We're going to be the faces who people come in and see. We own the restaurant. We'll be bussing tables. We'll be talking to people. We really played up that we had a lot of desire to build a neighborhood restaurant, not just a business.
Advertisement
Dim sum and drinks at Darling.
J-M Leach
Did you always want to work in restaurants?
Definitely not. I got a job when I was home for the summer during college as a busboy in Stamford, Connecticut. I went back to school that fall and lied on my resume a little bit to get myself a serving position at an Applebee's.
Restaurants for the first six or seven years were just a means for spending money. I was trying to be a musician. I play guitar. I was into folk music. I wanted to be Bob Dylan.
When it was clear I wasn't good enough for that, I tried to work in the music industry. When I moved to Boston, I was working out of this guy's apartment, booking shows and doing marketing for super local artists. I got paid 50 bucks a week. I was at Grafton Street then, serving. When a barback position opened up, I kind of thought it would be something cool. That's really when things clicked: the dynamic of being behind the bar as opposed to serving tables on the floor.
Advertisement
This was in the 2010s, when it felt like bartending was really starting to become something that you could make a career out of. I put all my eggs in that basket, and I just went for it.
How do you think the Boston hospitality scene has evolved since you arrived in the city?
Guests are so much savvier than when I first started. That goes for the industry, too. We've all kind of grown together, as bars start to evolve. Guests become more acclimated with certain techniques and ingredients and stuff.
The people who are coming up now are just very impressive. I think people are very loyal to spaces they work at, but they also treating [themselves] as a brand as well, and that's something I was never very good at.
If you had to classify Darling as a brand, what's the tagline?
Man. I'm still kind of trying to figure that out. We just want to be a cool but unpretentious place to hang out. We want to be a neighborhood cocktail bar, a place where people feel like they can come in whatever form they're in, dressed up or dressed down, to have a cocktail or to have a full dinner. I don't know if that's the perfect answer.
There are no perfect answers. What did you learn from working for Tiffani Faison at Tiger Mama?
That was definitely a pretty major introduction to the showbiz-y side of the industry. When I came to Tiger Mama, I didn't know who Tiffani was. I was just looking to work at a cool bar, and I didn't really have enough experience to work there. I got pretty fortunate.
Advertisement
I'd never watched 'Top Chef.' That was all very out of left field to me. To see people in the restaurant wanting to take pictures with her was a little confusing at first.
As I grew in that company and got closer with her, and started to go to certain events and everything, she showed me what's possible — again, how to treat yourself as a brand. Like I said, I don't think I'm very good at it, but I definitely learned a lot about that from her.
Your expertise is hospitality and drinks; you're not a marketing expert. I think it would be hard to do both.
Some people seem to be very good at it and make it look very easy. Even now, I'm doing a lot of social media for Darling, and I'm just kind of winging it. Some people can go in and make all these cool reels and videos and everything. I said this to someone the other day: I feel like my parents, when they don't know how to use a phone or an app.
How important do you think social media and branding is in this era of restaurants? Or does it matter as much as we might think it could?
I think it does matter. I think it probably doesn't matter as much as maybe sometimes we make it out to seem.
One of the challenges I've always had, especially as a younger bar manager, was just paying a lot of attention and putting a lot of energy into 'best of' lists and attention on social media.
You kind of start to feel like, if you don't have that, then you're not doing a good job. But then people are coming into the bar and they're having a nice time. But you have this feeling of ... for me, a lot of the time at Tiger Mama was: We were busy, people loved the drinks and everything, but I had this feeling of emptiness, because I didn't feel like I was having all of those [social media] things.
Advertisement
And after COVID, I really got rid of all that: I just don't care anymore.
Who do you really admire now? Who are people to watch?
What Ryan Polhemus is doing with Offsuit is really impressive. I've had the ability to work with him as I've been getting ready for this. I learned a lot from him about running a more cocktail-focused space. I just think he's extremely creative and talented when it comes to cocktails.
The guys over at Tall Order, Daren [Swisher] and Joe [Cammarata], were going through a lot of the process of opening restaurants around the same time. I like observing them as bartenders who have gone on to owners. It's definitely been very encouraging and informative. I think what they're doing is really great.
Where do you hang out when you're not working?
I've been in Andover, and I have a 2-year-old, so I haven't gone out in about two years. But we just moved to Watertown.
I lived for a while in Somerville, and I love Sarma. It's probably my favorite restaurant in the city. Offsuit is probably my favorite bar in the city. And I think Koji Club is doing a lot of really cool stuff. It's definitely a neat space for Boston. And I think what the team does at Spoke in Davis Square is really exciting.
What do you love to eat?
Pepperoni pizza is a big one. I was fortunate to live not far from Garlic Breath when I was up in Andover, which became my go-to. I've also been really just crushing PB&Js lately like nobody's business.
Crunchy or creamy?
Creamy.
Any great hangover cures?
I did get pretty hung over back in January, and I forced myself to run three miles the next morning, which was terrible, but then I felt pretty great. And then I went out for some spicy food and had a cheap lager. I would say that's my new plan. I actually felt surprisingly great. Usually, my hangover cure is to just lie on the couch and be miserable and not talk to anybody or do anything for the whole day.
There's been a lot of reporting that Gen Z
than previous generations. How has that influenced your work? Or is that not something you notice day to day?
I mean, it definitely seems to be real. It's definitely something I think a lot about, especially opening a bar right now. We're putting a lot of attention into NA beverages. You have to put the effort into that, in today's industry, if you want to be competitive.
How do you balance work with a
2-year-old?
It's honestly been really tough. I'm actually getting a little emotional: It's been, definitely, the hardest two years of my life. I have a really great partner and a really great support system, and that's the only way that it's possible. My wife is incredible.
When I was working on this space, it was tough. I was doing a lot of the R&D and everything from home. I'd get up with him; we'd put him down for a nap at 10; and then I'd run downstairs, work on an ingredient or jump on my laptop and fire off a bunch of emails for the hour-and-a-half that I had while he was asleep. I underestimated how difficult it would be. You just kind of figure it out.
On that note: Favorite drink?
A gin martini.
Interview was edited and condensed
.
Kara Baskin can be reached at

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
Is Johnson & Johnson a Good Dividend Stock to Buy Now?
Key Points Johnson & Johnson reported second-quarter results on July 16. Sales of pharmaceuticals have been muted due to a loss of market exclusivity for Stelara. A strong medical technology segment and an expanding pharmaceutical business could keep pushing the dividend higher despite patent expirations. 10 stocks we like better than Johnson & Johnson › For decades, Johnson & Johnson (NYSE: JNJ) stock was favored by investors seeking steady gains. Looking at its post-COVID-19 performance, though, steady gains aren't what investors received. When the market closed on Tuesday, July 15, shares of Johnson & Johnson or J&J, were down 7.5% in the year to date and about 17% below the all-time high the stock set back in 2022. Recent stock price movements don't jibe with the company's performance. When reporting second-quarter results before the market opened on July 16, management raised its sales outlook for the year. J&J's stock price is down from its 2022 peak, but it's performed better than you might think by simply looking at its chart. In 2023, shareholders received new shares of Kenvue, which used to be the conglomerate's consumer health division. Plus, this April, it raised its dividend payout for the 63rd year in a row. Let's take a closer look at J&J's performance through the first half of 2025 to see if it's still a good dividend stock to buy now. Reasons to buy Johnson & Johnson stock now The healthcare conglomerate's latest dividend increase of 4.8% raised the quarterly payout to $1.30 per share. At recent prices, that works out to a 3.3% yield. Sales of Listerine and Q-tips were reliable, but they didn't grow very fast. Now that J&J is a two-segment business focused on drugs and medical technology, overall sales growth at a mid-to-high single-digit percentage over the long run seems likely. Despite recently losing patent-protected market exclusivity for Stelara, a blockbuster treatment for psoriasis and Crohn's disease, J&J reported second-quarter pharmaceutical sales that rose by 4.9% year over year. Now that Stelara is responsible for less than 7% of total revenue, continued losses to biosimilar competition will be much easier to overcome with growing sales of newer products. There are more than enough new products in J&J's product lineup to overcome Stelara losses and continue growing earnings. For example, the FDA approved Spravato for treatment-resistant depression last year. In the first half of 2025, sales of the drug bounded 48% higher year over year to an annualized $1.5 billion. Caplyta, a treatment for schizophrenia and bipolar depression that J&J acquired in April, could surge in 2026. Earlier this month, J&J submitted an application that could make it a popular treatment for preventing relapses of schizophrenia. In a clinical trial supporting the application, treatment with Caplyta reduced the risk of relapse by 63% compared to the placebo group. The intellectual property protecting sales of medical technology lasts a lot longer than drug patents. With a new robotic surgical system on the way, J&J could have a powerful growth driver that boosts profits for decades. In April, surgeons completed the first cases in a clinical trial for the Ottava Robotic Surgical System. Competing with Intuitive Surgical won't be easy. With heaps of resources, J&J has a chance to gain a significant share of the lucrative surgical robotics space. Even without any contribution from Ottava, second-quarter MedTech sales rose by 7.3% year over year. Aging populations in developed nations will need plenty of cardiovascular interventions and hip replacements in the decades ahead. As a leader in these niches, continued growth at the present pace is a reasonable expectation. Don't expect huge gains With intellectual property that doesn't last long, pharmaceutical businesses are made of many pieces moving in opposite directions. Stelara accounted for about 11.7% of total revenue in 2024, making it the biggest patent cliff the company has to deal with at the moment. Multiple myeloma treatment Darzalex is currently responsible for 14.9% of total revenue. The main patents protecting U.S. market exclusivity for Darzalex expire in 2029. Stelara losses in the present and Darzalex losses several years from now mean we aren't likely to see overall sales growth at a double-digit percentage over the long run. That said, we can reasonably expect forward movement at a high-single-digit annual percentage. In the second quarter alone, J&J reported successful clinical trial results for over a dozen compounds that could support new drug approvals or expansions of addressable patient populations for existing treatments. If you're interested in a dividend payout that grows steadily, this is the stock for you. If rapid principle appreciation is what you're after, though, it's probably best to keep looking. Should you invest $1,000 in Johnson & Johnson right now? Before you buy stock in Johnson & Johnson, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Johnson & Johnson wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $679,653!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,046,308!* Now, it's worth noting Stock Advisor's total average return is 1,060% — a market-crushing outperformance compared to 179% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 15, 2025 Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Intuitive Surgical and Kenvue. The Motley Fool recommends Johnson & Johnson and recommends the following options: long January 2026 $13 calls on Kenvue. The Motley Fool has a disclosure policy. Is Johnson & Johnson a Good Dividend Stock to Buy Now? was originally published by The Motley Fool Sign in to access your portfolio


New York Times
8 hours ago
- New York Times
Late Night Fact-Checks Trump on His Uncle and the Unabomber
Welcome to Best of Late Night, a rundown of the previous night's highlights that lets you sleep — and lets us get paid to watch comedy. Here are the 50 best movies on Netflix right now. Weird Flex, Bro At an A.I. conference in Pennsylvania on Tuesday, President Trump said his uncle, John Trump, had been the 'longest-serving professor in the history of M.I.T.' and held 'three degrees in nuclear, chemical, and math.' Trump added that his uncle's students had included Ted Kaczynski, who he described as being 'seriously good.' 'Wow, we went from zero to Unabomber like that,' Jordan Klepper said on Wednesday's 'Daily Show,' snapping his fingers. Klepper pointed out that while the president's uncle had indeed been a well-known M.I.T. professor, he was not the longest-serving one, nor did he have degrees in 'nuclear, chemical and math' (he had a Ph.D. in electrical engineering). He said it was also highly unlikely that he had told his nephew Donald a story about teaching the Unabomber, 'because nobody knew who Kaczynski was until 1996, and Trump's uncle died in 1985.' 'Kaczynski did not go to M.I.T. He went to Harvard. [imitating Trump] 'Yes, but sometimes old Ted would take the crosstown bus over to M.I.T, then he would go around correcting people. He'd say, 'I actually didn't go to school here, you know, you don't actually know me. I'm a figment of the imagination of your dumbest nephew.'' — STEPHEN COLBERT 'So the whole thing we just heard wasn't just a small lie, it was like a full hallucination.' — SETH MEYERS 'Now, maybe, maybe, maybe, maybe Trump just misspoke, made a slip. I mean, who among us hasn't accidentally told people that our uncle taught the Unabomber?' — JORDAN KLEPPER 'What I'm saying is, isn't it great that we finally have a president whose brain works perfectly?' — JORDAN KLEPPER The Punchiest Punchlines (Snoozefest Edition) 'But the big story today is that Trump lashed out at his own supporters who are criticizing him over the Epstein files, calling them 'weaklings who have bought into B.S. hook, line and sinker.' Trump hasn't been this mad at the people he loved since McDonald's introduced salads.' — JIMMY FALLON 'No, he's right. The Epstein saga is a total snoozefest. I mean, the most powerful man in the world is blocking information about a cabal of the rich, the famous and the royal befriending a con man, who regularly flies off on his private plane to his private island to do super-illegal sex stuff. Then the con man is arrested, people are afraid he's going to name names, but before he can, he mysteriously dies right after being taken off of suicide watch in a federal prison during the administration of the guy who is blocking the release of the information. Boring!' — STEPHEN COLBERT Want all of The Times? Subscribe.
Yahoo
15 hours ago
- Yahoo
JNJ Begins Drug Sector Q2 Earnings With a Beat & Guidance Raise
Johnson & Johnson's JNJ second-quarter 2025 earnings came in at $2.77 per share, which beat the Zacks Consensus Estimate of $2.66. Earnings, however, declined 1.8% from the year-ago period. Adjusted earnings exclude intangible amortization expense and special items. Including these items, reported earnings were $2.29 per share, up 18.7% year over year. Sales of this drug and medical devices giant came in at $23.74 billion, which also beat the Zacks Consensus Estimate of $22.80 billion. (Find the latest earnings estimates and surprises on Zacks Earnings Calendar.) Sales rose 5.8% from the year-ago quarter, reflecting an operational increase of 4.6% and a positive currency impact of 1.2%. Organically, excluding the impact of acquisitions/divestitures and currency, sales rose 3.0% on an operational basis. Second-quarter sales in the domestic market rose 7.8% to $13.54 billion. Excluding the impact of all acquisitions and divestitures on an adjusted operational basis, domestic sales rose 5.0% in the quarter. International sales rose 3.2% on a reported basis to $10.2 billion, reflecting an operational increase of 0.6% and a positive currency impact of 2.6%. Excluding the impact of all acquisitions and divestitures on an adjusted operational basis, international sales rose 0.4% in the quarter. J&J's Innovative Medicines Unit Outperforms, MedTech Misses With the complete separation of the Consumer Health segment into a newly listed company called Kenvue KVUE in 2023, J&J has now become a two-sector company focused on the Pharmaceutical and MedTech fields. KVUE will report its second-quarter results in early August. J&J's Innovative Medicines segment sales rose 4.9% year over year to $15.2 billion, reflecting a 3.8% operational increase and a positive currency impact of 1.1%. Excluding the impact of all acquisitions and divestitures and currency on an adjusted operational basis, worldwide sales rose 2.4%. Innovative Medicines sales beat the Zacks Consensus Estimate of $14.55 billion as well as our model estimate of $14.50 billion. Higher sales of key products such as Darzalex, Tremfya and Erleada due to strong market growth and share gains drove the segment's growth. Xarelto and Simponi/Simponi Aria sales also rose in the quarter. New drugs like Carvykti, Tecvayli, Talvey, Rybrevant and Spravato contributed significantly to growth. The sales growth was partially dampened by lower sales of Imbruvica and generic/biosimilar competition to drugs like Stelara and Zytiga. JNJ's Oncology Drugs' Performance Sales of blockbuster multiple myeloma medicine Darzalex rose 23.0% year over year to $3.54 billion in the quarter. Sales beat the Zacks Consensus Estimate of $3.45 billion and our model estimate of $3.44 billion. Imbruvica sales declined 4.5% to $735.0 million. Rising competitive pressure in the United States due to new oral competition has been hurting Imbruvica's sales for the past few quarters. Imbruvica sales were, however, better than the Zacks Consensus Estimate of $697.0 million and our estimate of $694.8 million. Erleada generated sales of $908.0 million in the quarter, up 23.4% year over year. Erleada sales beat the Zacks Consensus Estimate of $853.0 million as well as our model estimate of $903.9 million. New drug Carvykti recorded sales of $439.0 million compared with $369 million in the previous new drug, Tecvayli, recorded sales of $166.0 million in the quarter, up 23.1% year over year, Sales of Talvey were $106 million, up 55.0% year over year. Rybrevant/Lazcluze sales were $179 million compared with $69 million in the year-ago quarter. Zytiga sales declined 11.6% to $145.0 million in the quarter due to generic competition. JNJ's Immunology Drugs' Performance Sales of the blockbuster psoriasis drug, Stelara, declined 42.7% to $1.65 billion in the quarterdue to the impact of biosimilar competition and Part D redesign. While U.S. sales of Stelara declined 41.9%, international sales declined 44.2% in the quarter. Stelara sales missed the Zacks Consensus Estimate as well as our model estimates of $1.88 billion. Several biosimilar versions of J&J's multi-billion-dollar immunology drug, Stelara, have been launched in the United States in 2025. According to patent settlements and license agreements, Amgen AMGN, Teva Pharmaceutical Industries TEVA, Samsung Bioepis/Sandoz and some other companies have already launched Stelara biosimilars this year. Tremfya recorded sales of $1.19 billion in the quarter, up 31.0% year over year. Tremfya sales beat the Zacks Consensus Estimate of $1.08 billion as well as our model estimate of $1.09 billion. Simponi/Simponi Aria sales rose 28.6% to $690.0 million. Sales of Remicade rose 15.9% in the quarter to $455.0 million. JNJ's Neuroscience, PAH and Other Drugs' Performance In neuroscience, Spravato recorded sales of $414.0 million, up 53.3% year over year. Caplyta, added from the Apil acquisition of Intra-Cellular Therapies, recorded sales of $211 million in the quarter. Invega Sustenna/Xeplion/Invega Trinza/Trevicta sales declined 5.9% to $992.0 million in the quarter. Pulmonary arterial hypertension (PAH) drug Uptravi recorded sales of $476.0 million, up 11.7% year over year. Another PAH drug, Opsumit, recorded sales of $582.0 million, up 6.4% year over year. Xarelto sales rose 5.6% in the quarter to $621.0 million. Prezista sales declined 9.4% to $396.0 million. How Did JNJ's MedTech Segment Perform in Q2? MedTech segment sales came in at $8.54 billion, up 7.3% from the year-ago period, including an operational increase of 6.1% and a positive currency impact of 1.2%. MedTech segment sales beat the Zacks Consensus Estimate of $8.25 billion as well as our model estimate of $8.31 billion. Excluding the impact of all acquisitions and divestitures, and currency, on an adjusted operational basis, worldwide sales rose 4.1%. In the MedTech segment, over the past couple of quarters, gains from recent acquisitions of Shockwave and Abiomed, as well as continued uptake of new products, have been offset by continued headwinds in Asia Pacific, specifically in China and increased competitive pressure in U.S. electrophysiology for PFA ablation catheter. Sales in China are being hurt by the impact of the volume-based procurement (VBP) program. VBP is a government-driven cost containment effort in China. JNJ Ups 2025 Sales and EPS Guidance Range The company raised its sales expectations for 2025 by around $2.0 billion to reflect a strong operational performance coupled with currency tailwinds. The sales guidance was raised from a range of $91.0 billion-$91.8 billion to $93.2 billion-$93.4 billion. The sales range indicates growth in the range of 5.1%-5.6% versus the prior expectation of 2.6%-3.6%. Operational sales growth is expected in the range of 4.5%-5.0% (previously 3.3%-4.3%). Adjusted operational sales (excluding currency impact, acquisitions/divestitures) growth is expected in the range of 3.2%-3.7% (previously 2.0%-3.0%). The revenue figures exclude revenues from COVID-19 vaccine sales. The adjusted earnings per share guidance was raised from a range of $10.50-$10.70 to $10.80-$10.90. On an operational, constant-currency basis, adjusted earnings per share are expected to increase in the range of 8.2%-9.2% (previously 5.2% to 7.2%). Our Take on JNJ's Q2 Results J&J kicked off the earnings season for the drug and biotech sector with earnings and sales beats. Despite the loss of exclusivity ('LOE') of Stelara, its Innovative Medicines unit once again outperformed expectations, with sales of all key drugs Darzalex, Erleada and Tremfya beating estimates. The new drugs also contributed significantly to sales. Stelara LOE hurt revenue growth by 1170 basis points in the second quarter. MedTech unit's sales also beat estimates. J&J raised its sales and EPS guidance for the year. J&J's shares rose more than 2% in pre-market trading on Wednesday in response to the earnings beat and guidance raise. So far this year, J&J's stock has risen 9.1% compared with an increase of 1.9% for the industry. Image Source: Zacks Investment Research J&J's Innovative Medicine unit is showing a growth trend. In 2025, J&J expects growth in the Innovative Medicine segment in the face of Stelara biosimilar entrants to be driven by its key products such as Darzalex, Tremfya, Spravato and Erleada, as well as new drugs like Carvykti, Tecvayli and Talvey, and new indications for Tremfya and Rybrevant. J&J considers 2025 to be a 'catalyst year,' positioning the company for growth in the second half of the decade. J&J expects operational sales growth in both the Innovative Medicine and MedTech segments to be higher in the second half of the year than in the first. While newly launched products should drive growth in the Innovative Medicines segment in the second half, the MedTech segment may benefit from new products and easier comps. J&J is also making rapid progress with its pipeline and has been on an acquisition spree lately, which has strengthened its pipeline. However, the softness in the MedTech unit, the Stelara patent cliff and the potential impact of Part D redesign will be significant headwinds in 2025. It remains to be seen how the company navigates them. The legal battle surrounding its talc lawsuits is a persistent headwind. J&J's Zacks Rank J&J currently has a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Johnson & Johnson Price, Consensus and EPS Surprise Johnson & Johnson price-consensus-eps-surprise-chart | Johnson & Johnson Quote Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Johnson & Johnson (JNJ) : Free Stock Analysis Report Amgen Inc. (AMGN) : Free Stock Analysis Report Teva Pharmaceutical Industries Ltd. (TEVA) : Free Stock Analysis Report Kenvue Inc. (KVUE) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research